OneSource clarifies no material impact from DRL Semaglutide supply delay

Business Updates View source PDF Explain this filing

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹1612.00

prior close

₹1652.60

announcement price

In-mkt

timing

Nifty Smallcap 250market+1.6%-0.8% vs market

Pharmaceuticals peers, median of 166sector+0.9%-0.1% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.1

15m

-0.1

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8+1.6-0.8+0.9-0.1

Next day

+1.2+3.0-1.7+1.4-0.2

+3.7+3.3+0.5+1.7+2.0

+2.2+2.1+0.1+1.3+0.9

+1.5+2.8-1.4+1.6-0.1

+2.3+2.9-0.6+1.5+0.8

+4.5+2.4+2.1+1.2+3.3

15d

+4.7+1.4+3.3-0.6+5.4

-1.7+4.2-5.9+0.8-2.4

-4.5+4.7-9.2+2.7-7.2

-9.7-0.1-9.6-0.8-9.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

OneSource Specialty Pharma clarified that Dr. Reddy's Laboratories delay in commercial supplies of Semaglutide will not have any material impact on its operations. The company said it has enough demand from other customers including Canada, with capacities fully committed. New capacity additions planned this quarter and later this year will allow OneSource to meet DRL's demand once DRL is ready to resume.

Likely market impact

Reassurance for investors: DRL's delay will not hurt OneSource's finances; demand and capacity remain strong.